EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Affordable Pricing of CRISPR Treatments is a Pressing Ethical Imperative

Jon Rueda iD, Íñigo de Miguel Beriain iD, Lluis Montoliu iD

The CRISPR Journal · 2024

DOI: 10.1089/crispr.2024.0042 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The CRISPR Journal, 2024. Verfasst von Jon Rueda und 2 weiteren Autor:innen. Beteiligte Einrichtung: University of Basque Country, Leioa, Bizkaia, Spain. Hauptthemen laut MEDLINE: Genetic Therapy, CRISPR-Cas Systems, Gene Editing, Clustered Regularly Interspaced Short Palindromic Repeats. Die Arbeit wurde bisher 36-mal zitiert (Crossref) und nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Casgevy, the world’s first approved CRISPR-based cell therapy, has been priced at $2.2 million per patient. Although this hefty price tag was widely anticipated, the extremely high cost of this and other cell and gene therapies poses a major ethical issue in terms of equitable access and global health. In this Perspective, we argue that lowering the prices of future CRISPR therapies is an urgent ethical imperative. Although we focus on Casgevy as a case study, much of our analysis can be extrapolated to the controversies over affordable access to other gene and cell therapies. First, we explain why this first-of-its-kind CRISPR therapy might be so expensive. We then analyze the ethical issues of equity and global health of early CRISPR treatments. Next, we discuss potential solutions to lower the prices of CRISPR gene therapies. We conclude that the approval of CRISPR transforms our obligations of justice and compels us to bring future gene therapies to the maximum possible number of patients with serious genetic diseases at affordable prices.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Genetic TherapyCRISPR-Cas SystemsGene EditingClustered Regularly Interspaced Short Palindromic RepeatsHumansCell- and Tissue-Based TherapyCosts and Cost Analysis

Autor:innen und Institutionen

  • University of Basque Country, Leioa, Bizkaia, Spain.
  • Filo-Lab Scientific Unit of Excellence, University of Granada, Granada, Spain.
  • Basque Foundation for Science, Leioa, Bizkaia, Spain.
  • Department of Public Law, and Coordinator of the Chair in Law and Human Genome, University of the Basque Country, Leioa, Bizkaia, Spain.
  • Department of Molecular and Cellular Biology, Spanish National Research Council (CSIC), National Centre for Biotechnology (CNB), Madrid, Spain.
  • Centre for Biomedical Network Research on Rare Diseases (CIBERER-ISCIII), Madrid, Spain.

ORCID-Profile: Jon Rueda, Íñigo de Miguel Beriain, Lluis Montoliu

Zitieren

APA

Rueda, J., de Miguel Beriain, Í., & Montoliu, L. (2024). Affordable Pricing of CRISPR Treatments is a Pressing Ethical Imperative. The CRISPR Journal. https://doi.org/10.1089/crispr.2024.0042

Vancouver

Rueda J, de Miguel Beriain Í, Montoliu L. Affordable Pricing of CRISPR Treatments is a Pressing Ethical Imperative. The CRISPR Journal. 2024. doi:10.1089/crispr.2024.0042

BibTeX
@article{Rueda2024,
  author = {Rueda, Jon and de Miguel Beriain, Íñigo and Montoliu, Lluis},
  title = {Affordable Pricing of CRISPR Treatments is a Pressing Ethical Imperative},
  journal = {The CRISPR Journal},
  year = {2024},
  doi = {10.1089/crispr.2024.0042}
}
Kostenlos starten →